Literature DB >> 12776277

Hemodialysis and estrogen levels in postmenopausal (HELP) patients: The multicenter HELP study.

Holly Mattix Kramer1, Gary Curhan, Ajay Singh.   

Abstract

BACKGROUND: Low serum estrogen levels are associated with increased risk for hip fractures in healthy postmenopausal women. Although the rate of hip fractures is 4- to 24-fold greater in postmenopausal hemodialysis-dependent women (PHDW) compared with the general population, no published study has examined the prevalence of low serum estrogen levels or factors associated with low serum estrogen levels in this population.
METHODS: We measured serum estrone (E1) and total estradiol (E2) levels in PHDW and investigated the independent association between serum estrogen levels and demographic and dialysis-related factors.
RESULTS: Of 186 PHDW not administered postmenopausal hormones, 44% and 30% had low serum E1 (<15 pg/mL [55.50 pmol/L]) and total E2 levels (<5 pg/mL [18.35 pmol/L]), respectively. Serum E1 and total E2 levels were significantly lower in Caucasian women compared with non-Caucasian women and in women with a body mass index (BMI) less than 25 kg/m2 versus 25 kg/m2 or greater. After adjusting for age, BMI, dialysis vintage, dialysis dose, and history of bilateral oophorectomy, Caucasian race was associated with an increased risk for low serum E1 (odds ratio [OR], 3.42; 95% confidence interval [CI], 1.63 to 7.19) and total E2 levels (OR, 2.47; 95% CI, 1.11 to 5.49) compared with non-Caucasians. In addition, we noted a significant and independent association between BMI and serum estrogen levels. For every 1-kg/m2 increase in BMI, risk for low serum E1 and total E2 levels decreased by 12% (OR, 0.88; 95% CI, 0.83 to 0.94) and 15% (OR, 0.85; 95% CI, 0.80 to 0.91), respectively. No significant association was noted between age, dialysis vintage, or dialysis dose and low serum E1 or total E2 levels.
CONCLUSION: A substantial number of PHDW have low serum estrogen levels. Caucasian race and low BMI are independently associated with low serum estrogen levels in PHDW, whereas dialysis-related factors are not.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776277     DOI: 10.1016/s0272-6386(03)00357-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life.

Authors:  N Sugiya; A Nakashima; N Takasugi; A Kawai; K Kiribayashi; J Tanaka; N Kohno; N Yorioka
Journal:  Osteoporos Int       Date:  2010-07-22       Impact factor: 4.507

Review 2.  Traditional and Non-traditional Risk Factors for Osteoporosis in CKD.

Authors:  Hanne Skou Jørgensen; Karel David; Syazrah Salam; Pieter Evenepoel
Journal:  Calcif Tissue Int       Date:  2021-02-14       Impact factor: 4.333

3.  Relation between serum estradiol levels and mortality in postmenopausal female hemodialysis patients.

Authors:  Mehmet Tanrisev; Gulay Asci; Ozkan Gungor; Fatih Kircelli; Ebru Sevinc Ok; Mumtaz Yilmaz; Osman Z Sahin; Kezban Pinar Ozen; Gultekin Suleymanlar; Huseyin Toz; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2012-04-18       Impact factor: 2.370

4.  Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis.

Authors:  Hirokazu Honda; Masashi Ueda; Shiho Kojima; Shinichi Mashiba; Yuki Hirai; Nozomu Hosaka; Hiroki Suzuki; Masanori Mukai; Makoto Watanabe; Keiko Takahashi; Kanji Shishido; Tadao Akizawa
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-07       Impact factor: 8.237

5.  Increased risk of fatal infections in women starting peritoneal dialysis.

Authors:  Silvia Ros; Cesar Remón; Abdul Rashid Qureshi; Pedro Quiros; Bengt Lindholm; Juan Jesús Carrero
Journal:  Perit Dial Int       Date:  2013-10-01       Impact factor: 1.756

Review 6.  Providing Care for Transgender Persons With Kidney Disease: A Narrative Review.

Authors:  David Collister; Nathalie Saad; Emily Christie; Sofia Ahmed
Journal:  Can J Kidney Health Dis       Date:  2021-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.